METHODS AND COMPOSITIONS INVOLVING MICRORNA

• US 20110112173A1
• Filed: 09/24/2010
• Published: 05/12/2011
• Est. Priority Date: 05/28/2004
• Status: Active Grant

• Current Assignee: Asuragen, Inc.
• Original Assignee: Asuragen, Inc.
• Inventors: CONRAD, RICK, MOON, IVONNE, SHELTON, JEFFREY, LABOURIER, EMMANUEL, DEVROE, ERIC, SHINGARA, JACLYN, POWERS, PATRICIA, GOLDRICK, MARIANNA, BROWN, DAVID, KEIGER, KERRI
• Granted Patent: US 8,568,971 B2
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/3517 Marker; Tag
• CPC Class Codes: C12N 2310/3519 Fusion with another nucleic acid
• CPC Class Codes: C12N 2320/10 in screening processes
• CPC Class Codes: C12P 19/34 Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2525/207 siRNA, miRNA
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.

Claims

1-147. -147. (canceled)

148. A method for identifying a human patient suspected of having cancer as having a marker correlated with cancer based on an increase in miR-21 expression comprising:

a) analyzing miR-21 expression in a biological sample from the patient comprising cells suspected of being cancerous; and

,

b) identifying the patient as i) having a marker correlated with cancer if an increase in miR-21 expression compared to a noncancerous biological sample is detected in the lung sample or ii) as not having a marker correlated with cancer if the increase fails to be detected, wherein the compared biological samples are derived from the same tissue.

150. The method of claim 148, wherein the biological sample comprises breast tissue and the increase in miR-21 expression is correlated with breast cancer.

151. The method of claim 150, further comprising analyzing the sample for 1) an increase in miR-200B and/or 2) a decrease in miR-100, miR-126, miR-143, miR-145, and/or miR-205 compared to a noncancerous breast sample.

152. The method of claim 148, wherein the biological sample comprises colon tissue and the increase in miR-21 expression is correlated with colon cancer.

153. The method of claim 152, further comprising analyzing the sample for 1) an increase in miR-31, miR-106A, miR-200B, miR-203, or miR-223 and/or 2) a decrease in miR-125a, mir-130a, miR-133, miR-135A, miR-143, or miR-145 compared to a noncancerous colon sample.

154. The method of claim 148, wherein the biological sample comprises prostate tissue and the increase in miR-21 expression is correlated with prostate cancer.

155. The method of claim 154, further comprising analyzing the sample for 1) an increase in miR-15A, miR-29, or miR-141 and/or 2) a decrease in miR-188, miR-290, or miR-331 compared to a noncancerous prostate sample.

156. The method of claim 148, wherein the biological sample comprises thyroid tissue and the increase in miR-21 expression is correlated with thyroid cancer.

157. The method of claim 156, further comprising analyzing the sample for 1) an increase in miR-15A or miR-200B and/or 2) a decrease in miR-30A-as, miR-31, miR-135A, miR-138, miR-152, miR-199A-as, miR-203, or miR-331 compared to a noncancerous thyroid sample.

158. The method of claim 148, wherein the biological sample comprises bladder tissue and the increase in miR-21 expression is correlated with bladder cancer.

159. The method of claim 158, further comprising analyzing the sample for 1) an increase in miR-9as, miR-182, or miR-200B and/or 2) a decrease in miR-133, miR-143, or miR-145 compared to a noncancerous bladder sample.

149. (canceled)

160. A method for identifying a human patient as having a marker correlated with cancer based on an increase in miR-21 expression comprising:

a) obtaining from a patient a breast, colon, prostate, lung, thyroid, or bladder tissue sample comprising cells suspected of being cancerous; and

,

b) identifying the patient, based on a determination of the tissue sample, as i) having a marker correlated with cancer if there is an increase in miR-21 expression in the tissue sample compared to a noncancerous tissue of the same type as the tissue sample or ii) as not having a marker correlated with cancer if the increase fails to be detected.

162. The method of claim 160, wherein the tissue sample comprises breast cells.

163. The method of claim 160, further comprising treating the patient for cancer after the patient is identified as having a marker correlated with cancer.

164. The method of claim 160, wherein the tissue sample comprises breast cells and the increase in miR-21 expression is correlated with breast cancer.

165. The method of claim 164, further comprising analyzing the sample for 1) an increase in miR-15a, miR-16, miR-24, miR-25, or miR-200B and/or 2) a decrease in miR-99, miR-100, miR-126, miR-135A, miR-143, miR-145, miR-197, miR-205, miR-211, miR-298 compared to a noncancerous breast sample.

166. The method of claim 160, wherein the tissue sample comprises colon tissue and the increase in miR-21 expression is correlated with colon cancer.

167. The method of claim 166, further comprising analyzing the sample for 1) an increase in miR-31, miR-106A, miR-200B, miR-203, or miR-223 and/or 2) a decrease in miR-125a, mir-130a, miR-133, miR-135A, miR-143, or miR-145 compared to a noncancerous colon sample.

168. The method of claim 160, wherein the tissue sample comprises prostate tissue and the increase in miR-21 expression is correlated with prostate cancer.

169. The method of claim 168, further comprising analyzing the sample for 1) an increase in miR-15A, miR-29, or miR-141 and/or 2) a decrease in miR-188, miR-290, or miR-331 compared to a noncancerous prostate sample.

170. The method of claim 160, wherein the tissue sample comprises thyroid tissue and the increase in miR-21 expression is correlated with thyroid cancer.

171. The method of claim 170, further comprising analyzing the sample for 1) an increase in miR-15A or miR-200B and/or 2) a decrease in miR-30A-as, miR-31, miR-135A, miR-138, miR-152, miR-199A-as, miR-203, or miR-331 compared to a noncancerous thyroid sample.

172. The method of claim 160, wherein the tissue sample comprises bladder tissue and the increase in miR-21 expression is correlated with bladder cancer.

173. The method of claim 172, further comprising analyzing the sample for 1) an increase in miR-9as, miR-182, or miR-200B and/or 2) a decrease in miR-133, miR-143, or miR-145 compared to a noncancerous bladder sample.

161. (canceled)

174. A method for identifying a patient as having a marker correlated with cancer based on an increase in miR-21 expression comprising:

a) analyzing miR-21 expression in a breast, colon, prostate, lung, thyroid, or bladder sample from a patient suspected of having cancer; and

,

b) identifying the patient as having a marker correlated with cancer if an increase in miR-21 expression of at least 50% in the patient'"'"'s biological sample compared to a noncancerous comparable sample is determined;

or identifying the patient as not having a marker correlated with cancer if the increase is not determined.

176. The method of claim 174, further comprising analyzing the sample for a decrease in miR-143 and/or an increase in miR-200b compared to a noncancerous comparable sample.

175. (canceled)

177. (canceled)

178. (canceled)

179. (canceled)